IMRX Stock — Immuneering Corporation: Cash, EV, Pipeline

Share price

$4.48

Market cap

$289.8M

Cash

$149.9M

Enterprise value

$139.9M

Balance sheet

Cash	$149.9M
Debt	$0.0M
Net cash	$149.9M
Enterprise value	$139.9M
Basic shares	64.7M shares
Fully diluted shares	81.2M shares
Fully diluted market cap	$363.8M
Cash per share	$2.32

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IMRX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Atebimetinib	Phase 3	Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Atebimetinib

Phase 3 · Active Modality: small molecule (once-daily oral)

Aliases IMM-1-104

Target MEK (Deep Cyclic Inhibition of MAPK pathway)

Indications

Advanced solid tumors with RAS or RAF mutations (Phase 1)
First-line pancreatic cancer (with modified gemcitabine/nab-paclitaxel) (Phase 3)

Status note Lead product candidate. Phase 3 registrational MAPKeeper 301 in first-line pancreatic cancer (combination with modified gemcitabine/nab-paclitaxel); Phase 1/2a in advanced solid tumors with RAS/RAF mutations. Additional early-stage programs unnamed in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Atebimetinib
Lead indication	Pancreatic Cancer
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07562152	Phase 3	Recruiting	Sponsor	IMRX	—	Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC	—
NCT05585320	Phase 2	Active, not recruiting	Sponsor	IMRX	—	Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Immuneering Corporation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

IMRX — Immuneering Corporation